Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Brief Summary: The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.


Options:
A: Arm Label: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Placebo for Nivolumab, Biological: Placebo for Ipilimumab | Arm Label: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Biological: Placebo for Nivolumab | Arm Label: Arm C: Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab
B: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
C: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pembrolizumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)

Answer: A